NIH Panel Issues April 29 Update to COVID-19 Treatment Guidelines
April 29, 2022
NIH Panel Issues April 29 Update to COVID-19 Treatment Guidelines
The COVID-19 Treatment Guidelines Panel (the Panel) has released a revised version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.
The Guideline updates include:
- The Definition for the C strength of recommendation rating (optional) has been changed from “optional” to “weak” to better reflect the strength of the Panel’s recommendations.
- New dosing guidance has been added to Prevention of SARS-CoV-2 Infection for people who received an initial dose of tixagevimab 150 mg plus cilgavimab 150 mg for pre-exposure prophylaxis (PrEP).
- The Ivermectin section was updated with the results from 2 recent, large randomized controlled trials. The Panel now recommends against the use of ivermectin for the treatment of COVID-19, except in clinical trials.
- Anti-SARS-CoV-2 Monoclonal Antibodies recommendations now include information on the role of bebtelovimab in the treatment of nonhospitalized patients with mild to moderate COVID-19 who are at high risk of progression. Also, sotrovimab is no longer recommended as a treatment option for patients with COVID-19 because it has substantially reduced in vitro activity against the Omicron BA.2 subvariant.
- The COVID-19 Convalescent Plasma section has been revised to reflect changes to the COVID-19 convalescent plasma (CCP) EUA and the Panel’s latest recommendations.
For complete details on these updates, please see What's New in the Guidelines on the COVID-19 Treatment Guidelines website.